Advertisement


Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?

2025 ASCO Annual Meeting

Advertisement

Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients with metastatic hormone-sensitive prostate cancer (Abstract 5004). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
On behalf of the ARASENS investigators, I was very pleased to present the ARASENS quality of life data. ARASENS is a phase three study in patients with metastatic hormone-sensitive prostate cancer. Patients were enrolled and were randomized to ADT plus darolutamide versus ADT and placebo to assess a primary endpoint of radiographic progression-free survival of darolutamide in this setting. Importantly, patients who were enrolled were predominantly high-volume metastatic disease and most had de novo metastatic hormone-sensitive disease. In terms of the quality of life analysis, patients were assessed by the Brief Pain. In the patients treated with ADT plus darolutamide versus ADT alone. I think also importantly the subscales of the FACT-P that were analyzed did suggest that certain subscales were improved more than others including urinary symptoms and prostate cancer-specific symptoms as well as functional well-being and social well-being, suggesting that patients were reporting that they had better time with their families and performing their daily activities. Ultimately, these suggest that darolutamide in the addition to ADT were improving metastatic hormone-sensitive prostate cancer patients' quality of life in addition to being associated with the radiographic progression-free survival advantage for this combination.

Related Videos

Lung Cancer

Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT

Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).  

Hematologic Malignancies

Andrew Kuykendall, MD, on Hepcidin Mimetic for Polycythemia Vera

Andrew Kuykendall, MD, of Moffitt Cancer Center, discusses findings from the phase III VERIFY trial, which compared the efficacy of rusfertide vs placebo in patients with polycythemia vera who continue their current standard of care therapy (Abstract LBA3). 

Shahzad Raza, MD, on Relapsed or Refractory AL Amyloidosis: First U.S. Trial of CAR T-Cell Therapy

Shahzad Raza, MD, of the Cleveland Clinic, reviews safety and efficacy data from Nexicart-2, the first U.S.-based trial of chimeric antigen receptor (CAR) T-cell therapy—an agent known as Nxc-201—in patients with relapsed or refractory light chain (AL) amyloidosis (Abstract 7508). 

Breast Cancer

Hope S. Rugo, MD, FASCO, and Rebecca Alexandra Dent, MD, FASCO, on Breast Cancer Data Highlights: Sequencing of Endocrine Therapy

Hope S. Rugo, MD, FASCO, of City of Hope, and Rebecca Alexandra Dent, MD, FASCO, of National Cancer Centre Singapore, review the results of a biomarker analysis of the DESTINY-Breast06 trial, which evaluated trastuzumab deruxtecan after endocrine therapy in patients with metastatic breast cancer (Abstract 1013). They also discuss findings from the SERENA-6 and EMBER-3 trials, also presented at ASCO 2025, and what all this new data means for the sequencing of endocrine therapy in patients with breast cancer. 

Lung Cancer

Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 

Advertisement

Advertisement




Advertisement